Sigilon Therapeutics to Present at the Needham Healthcare Conference

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will take place on Thursday, April 14, 2022 at 8:45 a.m. EDT.

A webcast of the presentation will be accessible through the investor section of the company’s website at www.sigilon.com, with a replay available for 90 days following the event.

About Sigilon TherapeuticsSigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor ContactRobert Windsor, Jr., J.D.VP, Head of Investor RelationsSigilon Therapeutics[email protected]617-586-3837

Media ContactAmy BonannoSolebury Trout[email protected]914-450-0349

You May Also Be Interested In

• Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
• Understanding Lymph System Support Supplements: PureHealth Research Highlights Natural Ingredients for Everyday Wellness
• Green Thumb Opens Its 24th Florida Location, RISE Dispensary Port St. Lucie, on August 22